Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Nearly 1 in 5 Trauma Patients in Chicago Area Treated in Ill-Equipped Hospita...
18 Jan 2017 at 5:55pm
With dramatic increases in shootings and homicides in Chicago in recent years, more and more patients are being taken to hospitals with traumatic injuries. Nearly one-fifth of patients who should have been taken to a designated level 1 trauma center from 2009 to 2013 were instead taken to community hospitals in the Chicago area that are not fully equipped to deal with these traumatic cases, according to a new study published today in JAMA Surgery. The city has long struggled with a lack of hospitals that are level 1 trauma centers, meaning they are designated specifically for the most serious types of traumatic injuries.
AP-NORC Poll: Americans of all stripes say fix health care
18 Jan 2017 at 4:33pm
Sylvia Douglas twice voted for President Barack Obama and last year cast a ballot for Democrat Hillary Clinton. But when it comes to "Obamacare," she now sounds like President-elect Donald Trump. ...
Blood pressure care in U.S. improving, but disparities remain
18 Jan 2017 at 4:11pm
By Andrew M. Seaman (Reuters Health) - Treatment of high blood pressure is improving in the United States, but a new study suggests white people are seeing more improvements than black or Hispanic people. Blacks and Hispanics were less likely to have their blood pressure under control, compared to whites, researchers found. The new study shows public health efforts to improve blood pressure control are working, but "there are still disparities that still affect minorities," said senior author Dr. Edgar Argulian, of Mt. Sinai St. Luke's Hospital in New York City.
FDA issues draft guidance to better medical product labeling
18 Jan 2017 at 3:56pm
(Reuters) - The U.S. health regulator issued draft guidance, recommending ways to communicate promotional materials and additional information that is not on the label of medical products. The U.S. Food and Drug Administration typically determines what information goes on the labels of medical drugs and devices, after evaluating whether the product is safe and effective for the proposed indication. If a firm communicates information, including on promotional material, that has not been evaluated by the regulator, but appears to be FDA-ratified, then it could lead to misbranding, and could subject firms to enforcement action if the representations or suggestions are considered false or misleading.
Startup League set for U.S. expansion, eyes next funding round
18 Jan 2017 at 3:56pm
By Solarina Ho TORONTO (Reuters) - League Inc, a Toronto-based startup that has excited investors because of its potential to streamline health benefits and the insurance market, will soon offer insurance products in the United States and complete its Canadian roll-out, its chief executive said on Wednesday. The two-year-old company is also eyeing overseas expansion and broadening its services this year, which could prompt another round of funding this fall or next spring, CEO and founder Michael Serbinis said in an interview. "Fall would be the first window to consider it." League lets businesses offer employees customized healthcare benefits through its app.
Father files suit against police in California for son's fatal shooting
18 Jan 2017 at 3:55pm
The father of Alfred Olango, an unarmed black man shot to death by police in Southern California last year, has filed a lawsuit against the officer involved and his department, accusing them of unjustly killing his son who was suffering from a mental breakdown. The slaying last September of Ugandan-born Alfred Olango, 38, in the San Diego suburb of El Cajon sparked several days of street protests after video of the deadly incident emerged online. The civil suit, filed on Friday in federal court in San Diego, came three days after local prosecutors announced that the officer who opened fire, Richard Gonsalves, would not be criminally charged for the shooting.
Canadian Pacific CEO Harrison to leave early
18 Jan 2017 at 3:50pm
Canadian Pacific Railway Ltd , Canada's No. 2 railroad operator, reported a lower-than-expected adjusted quarterly profit on Wednesday and said its chief executive would leave five months earlier than originally expected. Hunter Harrison will officially step down Jan. 31 and will take vacation leave with immediate effect. Last April, a company spokesman said Harrison planned to serve out his contract ending in June 2017.
Person-to-person contact may cause most drug-resistant TB cases
18 Jan 2017 at 3:04pm
By Gene Emery (Reuters Health) - The worst form of drug-resistant tuberculosis isn't just arising from inadequate treatment, it's mostly being spread from person to person, according to a new study of hundreds of cases in South Africa that has important implications for how the deadly disease is treated. Researchers tracked TB that is resistant to at least four key drugs and found that 69 percent of the victims had never received treatment, an indication that they had acquired it from others with extensively drug-resistant TB. "For many years, there was this thought that maybe drug-resistant TB strains might not be able to be transmitted as efficiently a regular TB strains," coauthor Dr. Neel R. Gandhi of Emory University?s Rollins School of Public Health in Atlanta told Reuters Health by phone.
Trump health pick defends stocks, says Americans won't lose insurance
18 Jan 2017 at 2:47pm
By Toni Clarke and Susan Cornwell WASHINGTON (Reuters) - President-elect Donald Trump's nominee to head the U.S. Department of Health and Human Services defended his stock holdings and proposals to dismantle Obamacare on Wednesday, saying Americans would not suddenly lose health insurance. Representative Tom Price told the Senate Committee on Health, Education, Labor and Pensions, one of two that oversee the health department, that there was no connection between his purchase of certain health company stocks and his promotion of legislation that would have helped the companies.
Business euphoria over Trump gives way to caution, uncertainty
18 Jan 2017 at 2:21pm
By Patrick Rucker and Sarah N. Lynch WASHINGTON (Reuters) - Early optimism among business lobbyists and executives that Donald Trump's election heralded better days has slowly given way to uncertainty as the president-elect fires off mixed and sometimes confusing messages on healthcare, taxes and trade. Some of that has frayed as questions arise over the nuts and bolts of Trump's campaign promises, although many in the business community said they remained optimistic. Doubts deepened over the weekend as Trump declared he would replace President Barack Obama's signature healthcare plan known as Obamacare with "insurance for everybody" - a goal far beyond Republican designs - and criticized a key component of a plan in Congress to overhaul corporate taxes.
Price tries to reassure on health care; Dems not buying it
18 Jan 2017 at 2:16pm
Offering reassurances, President-elect Donald Trump's pick for health secretary said Wednesday the new administration won't "pull the rug out" from those covered by "Obamacare." Democrats ...
Global coalition aims to outpace epidemics with new vaccines
18 Jan 2017 at 2:03pm
By Kate Kelland DAVOS, Switzerland (Reuters) - A global coalition of governments, health specialists and philanthropists will launch a new plan on Thursday to "outsmart" future disease epidemics with a fund to prepare and create new vaccines. Stung by the devastation of West Africa's 2014-2015 Ebola outbreak, which killed more than 11,300 people before an effective vaccine was developed, the coalition is aiming to ensure such deadly outbreaks can't happen again. John-Arne Rottingen, interim chief executive officer of the Coalition for Epidemic Preparedness Innovations (CEPI), said it is designed as "a global insurance policy against epidemic and pandemic threats".
Successful pregnancy possible even with heart defects
18 Jan 2017 at 1:57pm
By Lisa Rapaport (Reuters Health) - Women who are born with high-risk heart defects can have successful pregnancies if they get the right medical support, according to new U.S. guidelines. The guidelines are the first from the American Heart Association to offer a road map to women with congenital heart defects who have long been told to avoid pregnancy altogether, said Mary Canobbio, a researcher at the University of California, Los Angeles and chair of the committee that drafted the advice. ?Historically the tendency has been to advise these women to avoid pregnancy because the defect and surgeries done to keep these women alive are complex and the long term survival is difficult to predict ? so concern has been that the ?added burden? of pregnancy could potentially cause more problems and decrease their own long term survival,? Canobbio said by email.
Vape companies try to galvanize Trump administration to ease FDA rules
18 Jan 2017 at 12:55pm
As tobacco and vaping companies focus on new smoking products that are potentially less harmful, the industry sees an opening for rolling back rules on these products under the Trump administration. Donald Trump?s surprise election victory in November, and his pledges to reduce federal regulations on business, led tobacco lobby groups to draft a new plan of action, according to company executives, lobbyists and consultants interviewed by Reuters. The immediate goal is to delay implementation of new regulations on the latest generation of e-cigarettes and other vaping devices, which produce a vapor from liquid nicotine rather than burning tobacco.
Flabby heart keeps pumping with squeeze from robotic sleeve
18 Jan 2017 at 12:33pm
WASHINGTON (AP) ? Scientists are developing a robotic sleeve that can encase a flabby diseased heart and gently squeeze to keep it pumping.